| Dr James R Bukstein, MD | |
|
8500 Edinbrook Pkwy, Brooklyn Park, MN 55443-3720 | |
| (763) 425-1211 | |
| (763) 425-6277 |
| Full Name | Dr James R Bukstein |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 8500 Edinbrook Pkwy, Brooklyn Park, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366419772 | NPI | - | NPPES |
| 481295600 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 23483 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James R Bukstein, MD 8500 Edinbrook Pkwy, Brooklyn Park, MN 55443-3720 Ph: (763) 425-1211 | Dr James R Bukstein, MD 8500 Edinbrook Pkwy, Brooklyn Park, MN 55443-3720 Ph: (763) 425-1211 |
News Archive
Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, announced today that the Company closed its previously announced private placement with investors including Oracle Investment Management, Jack W. Schuler, Birchview Fund LLC and several Vermillion directors. Total proceeds were $10.5 million, before offering expenses.
The history of the pharmaceutical industry is closely linked to the business practices of the combination and purchase of corporations. From the creation of the combined entity of Warner-Lambert in 1955, to the purchase of Warner-Lambert by Pfizer in 2000, to the recent acquisition of Wyeth, pharmaceutical and biotech companies have expanded their pipelines, portfolios, and sales forces through mergers and acquisitions (M&A).
Researchers at the University of York are using an understanding of the special cells that line the bladder to develop ways of restoring continence to patients with serious bladder conditions, including cancer.
BioMS Medical Corp. today reported that Spectral Diagnostics has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxin(TM), a therapeutic hemoperfusion device for the treatment of severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxin(TM) in the United States.
Emisphere Technologies, Inc. today announced that Novartis Pharma AG and its license partner Nordic Bioscience a/s have reported the following in connection with their Phase III Study 2302 in osteoarthritis assessing the safety and efficacy of oral calcitonin in the treatment of osteoarthritis of the knee.
› Verified 3 days ago
Hyder Mohammad Khan, PH.D., MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7650 Zane Ave N, Brooklyn Park, MN 55443 Phone: 612-873-6963 | |
Bethany Leigh Templen, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 10000 Zane Ave N, Brooklyn Park, MN 55443 Phone: 763-569-6293 Fax: 763-569-6258 | |
Dr. Karen A. Arrett, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 8500 Edinbrook Pkwy, Brooklyn Park, MN 55443 Phone: 763-425-1211 Fax: 763-425-6277 | |
Dr. Lyn P. Chapman, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 8500 Edinbrook Pkwy, Brooklyn Park, MN 55443 Phone: 763-425-1211 Fax: 763-425-6277 | |
Dr. Trudie R. Sprenkle, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 8500 Edinbrook Pkwy, Brooklyn Park, MN 55443 Phone: 763-425-1211 Fax: 763-425-6277 | |
Dr. Jane M. Laco, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8500 Edinbrook Pkwy, Brooklyn Park, MN 55443 Phone: 763-425-1211 Fax: 763-425-6277 |